Cell line studies indicated that SPEC-2 cells (derived from ESC) had higher NRF2 levels and were more resistant to chemotherapy than Ishikawa cells (derived from endometrioid carcinoma) (14). The gene discussed is NFE2L2; the disease is endometrioid adenocarcinoma.